The ACR and Rheumatology Research Foundation hope a new report on rheumatic disease research can leverage more money for ACR members, funding future research…
Influential Lancet Article on HCQ Retracted
NEW YORK, June 4 (Reuters)—Three of the authors of an influential article that found hydroxychloroquine (HCQ) increased the risk of death in COVID-19 patients retracted the study, citing concerns about the quality of the data behind it. The anti-malarial drug has been controversial in part due to support from U.S. President Donald Trump, as well…
Are ANAs More Prevalent in the U.S. Now Than in the Past?
According to a new study, the prevalence of anti-nuclear antibodies (ANAs), the most common biomarker of autoimmunity in the U.S., has increased considerably in recent years among adolescents aged 12–19 years, in both sexes (especially in men), older adults (age ≥50 years) and non-Hispanic whites…
Researchers Discuss Viability of Rheumatology Education During the COVID‐19 Pandemic
In a matter of weeks, the COVID‑19 crisis has totally upended clinical medicine and the practice of rheumatology. Our old ways of seeing patients in person, precepting fellows in clinic or on the consult service, and leading in-person interactive teaching rounds are gone for now and possibly for good. But how can we replace these…
9/11 Survivors at Increased Risk for Autoimmune Disease
Miller-Archie et al. set out to determine whether dust exposure and PTSD are associated with an increased risk of systemic autoimmune disease in a 9/11-exposed cohort not included in previous studies of members of the Fire Department of New York and whether this association differs between 9/11 responders and community members.
Finding Opportunity Through Challenge: Q&A with Vaneet K. Sandhu, MD, FACR, RhMSUS
The COVID-19 global pandemic is forcing telemedicine-only connections with patients and bringing existing rheumatology research to a standstill. However, these challenges are spurring opportunity and innovation, according to Vaneet K. Sandhu, MD, FACR, RhMSUS, director of rheumatology clinical operations at Riverside University Health System and associate fellowship program director in rheumatology at Loma Linda University…
COVID-19 Pandemic Leads Big Drugmakers to Hit Pause on Clinical Trials
(Reuters)—U.S. drugmakers Eli Lilly and Co. and Bristol Myers Squibb said they are delaying the start of new clinical trials in part to free up doctors and healthcare facilities to deal with the surge in patients infected with the new coronavirus. Lilly and Bristol are the biggest drugmakers yet to announce clinical trial delays in…
A Combined Immunosuppressive Regimen for ILD MDA5-Positive Dermatomyositis
Interstitial lung disease accompanied by anti-melanoma differentiation-associated gene 5 positive dermatomyositis is often rapidly progressive and associated with poor prognosis. In this study, a combined immunosuppressive regimen of high-dose glucocorticoids, tacrolimus and intravenous cyclophosphamide proved more effective than treatment with high-dose glucocorticoids and stepwise addition of an immunosuppressant in a historical control group.
The Third Choice: The Predatory Journal Scam
“Greetings of the day!” My email account used to be flooded by these cheerful salutations, referring to me as an esteemed colleague or a thought leader. I have to admit: at first, I enjoyed receiving these messages. Normally, when I log into my email account, I’m greeted by messages—punctuated by red, capital letters—that announce dire…
Emerging Biomarkers for Lupus
ATLANTA—When it comes to identifying reliable biomarkers that can predict worsening illness or help point to proper treatment, it’s hard to imagine a more vexing disease than systemic lupus erythematosus (SLE), said Jill P. Buyon, MD, director of the Lupus Center at New York University Langone Medical Center, in the 2019 ACR/ARP Annual Meeting session…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 78
- Next Page »